Vanqua Bio to Present Pre-Clinical Data on VQ-201, a Next Generation C5aR1 Antagonist for the Treatment of Inflammatory Disorders - Vanqua Bio CHICAGO, Dec. 05, 2024 (GLOBE NEWSWIRE) — Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at the 8th Annual Complement-Based Drug Development Summit, wh...

www.vanquabio.com/vanqua-bio-t...
Looking for this #C5aR1 data. If you attended, could you please share ?
#VanquaBio #InflaRx $IFRX #Biogen $BIIB

Controlling Life Threatening Inflammatory Diseases - Prof. Dr. Niels Riedemann, MD, Ph.D. - CEO, InflaRx, joins me on Progress, Potential, And Possibilities #NielsRiedemann #InflaRx #Inflammation #ComplementComponent5a #Sepsis #AcuteRespiratoryDistressSyndrome #Covid www.youtube.com/watch?v=fYt-...

45% coverage via pre funded wts is a double edged sword: if Baker Brothers 👍, if Susquehanna 👎. The price action (but also no mention of ANY investor by name in the PR) favours 👎...
Looks like a sloppy deal I'm afraid.
#IFRX $IFRX #InflaRx

Being a long time holder of $IFRX doesn't make me blind to short-term drivers. The one screaming at me: nobody dares to short the name even though it's up 60% in a biotech bear market. Borrowing cost at 0.8% down from 18%.
#ifrx #InflaRx